{
    "Trade/Device Name(s)": [
        "Creatinine",
        "Creatinine Reagent"
    ],
    "Submitter Information": "Abbott Laboratories",
    "510(k) Number": "K083809",
    "Predicate Device Reference 510(k) Number(s)": [
        "K061193",
        "K941837"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "CGX"
    ],
    "Summary Letter Date": "March 7, 2009",
    "Summary Letter Received Date": "March 10, 2009",
    "Submission Date": "December 15, 2008",
    "Regulation Number(s)": [
        "21 CFR 862.1225"
    ],
    "Regulation Name(s)": [
        "Creatinine test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Creatinine"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma",
        "Urine"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "AEROSET System",
        "ARCHITECT c8000 System",
        "Hitachi 917 Analyzer"
    ],
    "Method(s)/Technology(ies)": [
        "Modified Jaffe (alkaline picrate) methodology"
    ],
    "Methodologies": [
        "Spectrophotometric analysis"
    ],
    "Submission Type(s)": [
        "Assay",
        "Reagent"
    ],
    "Document Summary": "FDA 510(k) summary for Abbott Laboratories Creatinine assay (modified Jaffe method) for quantitation of creatinine in serum, plasma, and urine on AEROSET and ARCHITECT c8000 systems.",
    "Indications for Use Summary": "Device intended to measure creatinine levels in serum, plasma and urine for diagnosis and treatment of renal diseases, monitoring renal dialysis, and as a calculation basis for other urine analytes.",
    "fda_folder": "Clinical Chemistry"
}